Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1988 1
1990 3
1992 4
1993 1
1994 1
1995 2
1996 1
1997 1
1998 6
1999 2
2000 2
2001 1
2002 1
2003 2
2004 3
2005 2
2006 4
2007 5
2008 2
2009 4
2010 6
2011 6
2012 6
2013 4
2014 5
2015 7
2016 6
2017 7
2018 4
2021 3
2022 4
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 8744550

97 results

Results by year

Filters applied: . Clear all
Page 1
Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa-IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age.
Arístegui J, Dal-Ré R, Díez-Delgado J, Marés J, Casanovas JM, García-Corbeira P, De Frutos E, Van Esso D, Verdaguer J, De la Flor J, Moraga F, Boceta R, García-Martínez JA. Arístegui J, et al. Vaccine. 2003 Sep 8;21(25-26):3593-600. doi: 10.1016/s0264-410x(03)00420-1. Vaccine. 2003. PMID: 12922087 Clinical Trial.
Booster immunization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate combination vaccine in the second year of life: safety, immunogenicity and persistence of antibody responses.
Heininger U; DTP-HBV-IPV-059 Study Group; DTP-HBV-IPV-096 Study Group; Sänger R, Jacquet JM, Schuerman L. Heininger U, et al. Vaccine. 2007 Jan 22;25(6):1055-63. doi: 10.1016/j.vaccine.2006.09.060. Epub 2006 Oct 2. Vaccine. 2007. PMID: 17049692 Clinical Trial.
Immunogenicity and reactogenicity of two regimens of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio and Haemophilus influenzae type b vaccines administered to infants primed at birth with hepatitis B vaccine.
Cheng HK, Rajadurai VS, Amin Z, Sriram B, Yee MF, Han HH, Bock HL, Safary A. Cheng HK, et al. Southeast Asian J Trop Med Public Health. 2004 Sep;35(3):685-92. Southeast Asian J Trop Med Public Health. 2004. PMID: 15689088 Clinical Trial.
Immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (Tdap-IPV; Repevax) administered concomitantly versus non-concomitantly with an influenza vaccine (Vaxigrip) to adults aged ≥60 years: an open-label, randomised trial.
Zimmermann U, Gavazzi G, Richard P, Eymin C, Soubeyrand B, Baudin M. Zimmermann U, et al. Vaccine. 2013 Mar 1;31(11):1496-502. doi: 10.1016/j.vaccine.2012.12.081. Epub 2013 Jan 10. Vaccine. 2013. PMID: 23313654 Clinical Trial.
Hepatitis B immune memory in children primed with hexavalent vaccines and given monovalent booster vaccines: an open-label, randomised, controlled, multicentre study.
Zanetti AR, Romanò L, Giambi C, Pavan A, Carnelli V, Baitelli G, Malchiodi G, Valerio E, Barale A, Marchisio MA, Montù D, Tozzi AE, D'Ancona F; study group. Zanetti AR, et al. Lancet Infect Dis. 2010 Nov;10(11):755-61. doi: 10.1016/S1473-3099(10)70195-X. Epub 2010 Sep 29. Lancet Infect Dis. 2010. PMID: 20884297 Clinical Trial.
97 results